Skip to main content
Fig. 1 | BMC Pulmonary Medicine

Fig. 1

From: Clinical course of COPD patients with exercise-induced elevation of pulmonary artery pressure or less severe pulmonary hypertension presenting with respiratory symptoms and the impact of bosentan intervention—prospective, single-center, randomized, parallel-group study

Fig. 1

Patient flowchart. Targeted patients of patients with stable COPD who had not required any change of treatment within 3 months prior to study enrollment and with respiratory symptoms which were stable but remained and gradually progressed even after COPD therapy overtime, those with eePAP or less severe PH (no comorbidity other than COPD affecting ADL and RV strain) (mPAP < 25 mmHg and mPAPOE ≥ 30 mmHg or 25 mmHg ≤ mPAP < 35 mmHg). The study required that COPD patients be randomized to drug-treated and untreated groups to investigate their clinical course in real-world settings, with no change of treatment allowed including bosentan for 2 years or until their death as a rule, except for minimal symptomatic therapy including oxygen volume adjustments that met none of the exclusion criteria

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us